Akinori Wada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akinori Wada has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Akihiro Kawauchi
10 shared publicationsAkio Shimizu
9 shared publications- Hisakazu Ogita
Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology, Shiga University of Medical Science, Japan
9 shared publications Joanne Ern Chi Soh
9 shared publicationsKhurelbaatar Tsevelnorov
9 shared publicationsLe Kim Chi Nguyen
9 shared publications
Latest Publications
- Open Access
- 2 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Prostate cancer detection in routine clinical practice: a large cohort study in Japan
Population-based organized prostate-specific antigen (PSA) screening is implemented in 80% of Japanese municipalities; however, Shiga Prefecture remains a unique exception without such a systematic program. This study characterized the longitudinal clinical features and treatment patterns in this opportunistic testing environment using data from 1716 patients diagnosed via prostate biopsy in 2012, 2017, and 2022. While median PSA levels remained stable (10.40–11.43 ng/mL), median age at diagnosis increased from 72 to 74 years. Over the decade, the incidence of International Society of Urological Pathology Grade Group 1 and cT1c stages decreased significantly ( p < 0.001), with nearly 90% of cases being cT2 or higher in 2022. Risk classification showed a decrease in low-risk cases and a rise in high-risk cases. Regarding treatment, radical prostatectomy rates remained stable at approximately 25%, whereas the overall use of active surveillance (AS) increased from 1 to 9%. Notably, among low-risk patients, AS adoption rose markedly from 2.3% in 2012 to 68% in 2022. While clinical practices have evolved to successfully minimize unnecessary invasive intervention, these findings suggest that clinical progress alone cannot fully compensate for the lack of organized efforts to improve early detection.
- 2 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessProstate cancer detection in routine clinical practice: a large cohort study in Japan
Population-based organized prostate-specific antigen (PSA) screening is implemented in 80% of Japanese municipalities; however, Shiga Prefecture remains a unique exception without such a systematic program. This study characterized the longitudinal clinical features and treatment patterns in this opportunistic testing environment using data from 1716 patients diagnosed via prostate biopsy in 2012, 2017, and 2022. While median PSA levels remained stable (10.40–11.43 ng/mL), median age at diagnosis increased from 72 to 74 years. Over the decade, the incidence of International Society of Urological Pathology Grade Group 1 and cT1c stages decreased significantly ( p < 0.001), with nearly 90% of cases being cT2 or higher in 2022. Risk classification showed a decrease in low-risk cases and a rise in high-risk cases. Regarding treatment, radical prostatectomy rates remained stable at approximately 25%, whereas the overall use of active surveillance (AS) increased from 1 to 9%. Notably, among low-risk patients, AS adoption rose markedly from 2.3% in 2012 to 68% in 2022. While clinical practices have evolved to successfully minimize unnecessary invasive intervention, these findings suggest that clinical progress alone cannot fully compensate for the lack of organized efforts to improve early detection.
- Open Access
- 1 January 2026
- Published by Wiley in Asian Journal of Endoscopic Surgery
- Vol. 19 (1) , e70326
Comparison of Surgical Outcomes Between the Hinotori and da Vinci Platforms in Robot‐Assisted Radical Prostatectomy: A Propensity Score‐Matched Study
Introduction: Comparative evidence between robotic platforms for robot‐assisted radical prostatectomy (RARP) remains limited, particularly regarding oncological quality beyond perioperative outcomes. This study compared outcomes between the hinotori and da Vinci systems, focusing on positive surgical margin (PSM) distribution in a real‐world cohort with varying surgeon experience. Methods: We reviewed 437 patients who underwent RARP at our institution between 2013 and 2025. After propensity score matching, 130 patients in the da Vinci group and 65 in the hinotori group were analyzed. Perioperative outcomes, PSM rates and anatomical distribution, urinary continence recovery, and biochemical recurrence (BCR)‐free survival were compared. Results: The matched cohort involved 17 surgeons, including 12 hinotori surgeons, with expert surgeons performing 38% of hinotori procedures. Operative, console, and setup‐related times were longer, and estimated blood loss was greater in the hinotori group. No transfusions were required. Complication rates and hospital stay were comparable. No differences were observed in overall or stage‐specific PSM rates. PSMs most frequently involved the apex and posterolateral regions in both groups, with no difference in anatomical PSM distribution. The 12‐month urinary continence recovery rates were 87% in the hinotori group and 85% in the da Vinci group. In the 2‐year time‐aligned analysis, BCR‐free survival rates in the hinotori and da Vinci groups were 94% and 89% at 1 year and 89% and 85% at 2 years, respectively. Conclusion: Hinotori‐assisted RARP showed longer operative and setup‐related times but no apparent deterioration in perioperative safety, PSM outcomes including anatomical distribution, continence recovery, or early BCR‐free survival.
- 1 January 2026
- Published by Wiley in Asian Journal of Endoscopic Surgery
- Vol. 19 (1) , e70326
Open AccessComparison of Surgical Outcomes Between the Hinotori and da Vinci Platforms in Robot‐Assisted Radical Prostatectomy: A Propensity Score‐Matched Study
Introduction: Comparative evidence between robotic platforms for robot‐assisted radical prostatectomy (RARP) remains limited, particularly regarding oncological quality beyond perioperative outcomes. This study compared outcomes between the hinotori and da Vinci systems, focusing on positive surgical margin (PSM) distribution in a real‐world cohort with varying surgeon experience. Methods: We reviewed 437 patients who underwent RARP at our institution between 2013 and 2025. After propensity score matching, 130 patients in the da Vinci group and 65 in the hinotori group were analyzed. Perioperative outcomes, PSM rates and anatomical distribution, urinary continence recovery, and biochemical recurrence (BCR)‐free survival were compared. Results: The matched cohort involved 17 surgeons, including 12 hinotori surgeons, with expert surgeons performing 38% of hinotori procedures. Operative, console, and setup‐related times were longer, and estimated blood loss was greater in the hinotori group. No transfusions were required. Complication rates and hospital stay were comparable. No differences were observed in overall or stage‐specific PSM rates. PSMs most frequently involved the apex and posterolateral regions in both groups, with no difference in anatomical PSM distribution. The 12‐month urinary continence recovery rates were 87% in the hinotori group and 85% in the da Vinci group. In the 2‐year time‐aligned analysis, BCR‐free survival rates in the hinotori and da Vinci groups were 94% and 89% at 1 year and 89% and 85% at 2 years, respectively. Conclusion: Hinotori‐assisted RARP showed longer operative and setup‐related times but no apparent deterioration in perioperative safety, PSM outcomes including anatomical distribution, continence recovery, or early BCR‐free survival.
- Open Access
- 7 August 2025
- Published by Wiley in International Journal of Urology
- Vol. 32 (11) , 1535-1543
Current Progress of Tissue Engineering With Stem Cells in Urology Updated Review in 2025
Tissue engineering, a key component of regenerative medicine, aims to restore the structure and function of damaged organs using combinations of cells, scaffolds, and bioactive factors. In urology, the integration of stem cell biology has fueled significant progress in preclinical models for kidney, bladder, and urethral regeneration. Pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells, offer broad differentiation potential, particularly in kidney organoid development. Meanwhile, multipotent stem cells—especially mesenchymal stem cells and urine‐derived stem cells—have shown promise in bladder and urethral repair due to their immunomodulatory properties and relative ease of use. Despite these advancements, certain challenges remain: vascularization, functional integration, long‐term safety, and scalability continue to limit the clinical application of regenerated organs. In kidney regeneration, issues such as nephron‐collecting duct connectivity and urinary outflow remain unresolved. For the bladder and urethra, the need for vascularized, contractile, and innervated tissue complicates scaffold and cell selection. Nonetheless, clinical translation is becoming increasingly realistic. As the field evolves rapidly, it is essential for urologists to remain informed and actively engage in collaborative research. By integrating clinical expertise with basic science, urologists can play a crucial role in guiding regenerative strategies toward effective, patient‐specific therapies.
- 7 August 2025
- Published by Wiley in International Journal of Urology
- Vol. 32 (11) , 1535-1543
Open AccessCurrent Progress of Tissue Engineering With Stem Cells in Urology Updated Review in 2025
Tissue engineering, a key component of regenerative medicine, aims to restore the structure and function of damaged organs using combinations of cells, scaffolds, and bioactive factors. In urology, the integration of stem cell biology has fueled significant progress in preclinical models for kidney, bladder, and urethral regeneration. Pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells, offer broad differentiation potential, particularly in kidney organoid development. Meanwhile, multipotent stem cells—especially mesenchymal stem cells and urine‐derived stem cells—have shown promise in bladder and urethral repair due to their immunomodulatory properties and relative ease of use. Despite these advancements, certain challenges remain: vascularization, functional integration, long‐term safety, and scalability continue to limit the clinical application of regenerated organs. In kidney regeneration, issues such as nephron‐collecting duct connectivity and urinary outflow remain unresolved. For the bladder and urethra, the need for vascularized, contractile, and innervated tissue complicates scaffold and cell selection. Nonetheless, clinical translation is becoming increasingly realistic. As the field evolves rapidly, it is essential for urologists to remain informed and actively engage in collaborative research. By integrating clinical expertise with basic science, urologists can play a crucial role in guiding regenerative strategies toward effective, patient‐specific therapies.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth
Supplementary Materials & Methods and Figures
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth
Supplementary Materials & Methods and Figures
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth
The growth and progression of cancers are crucially regulated by the tumor microenvironment where tumor cells and stromal cells are mutually associated. In this study, we found that stomatin expression was markedly upregulated by the interaction between prostate cancer cells and stromal cells. Stomatin suppressed cancer cell proliferation and enhanced apoptosis in vitro and inhibited xenograft tumor growth in vivo. Stomatin inhibited Akt activation, which is mediated by phosphoinositide-dependent protein kinase 1 (PDPK1). PDPK1 protein stability was maintained by its binding to HSP90. Stomatin interacted with PDPK1 and interfered with the PDPK1–HSP90 complex formation, resulting in decreased PDPK1 expression. Knockdown of stomatin in cancer cells elevated Akt activation and promoted cell increase by promoting the interaction between PDPK1 and HSP90. Clinically, stomatin expression levels were significantly decreased in human prostate cancer samples with high Gleason scores, and lower expression of stomatin was associated with higher recurrence of prostate cancer after the operation. Collectively, these findings demonstrate the tumor-suppressive effect of stromal-induced stomatin on cancer cells.Significance:These findings reveal that interactions with stromal cells induce expression of stomatin in prostate cancer cells, which suppresses tumor growth via attenuation of the Akt signaling axis.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth
The growth and progression of cancers are crucially regulated by the tumor microenvironment where tumor cells and stromal cells are mutually associated. In this study, we found that stomatin expression was markedly upregulated by the interaction between prostate cancer cells and stromal cells. Stomatin suppressed cancer cell proliferation and enhanced apoptosis in vitro and inhibited xenograft tumor growth in vivo. Stomatin inhibited Akt activation, which is mediated by phosphoinositide-dependent protein kinase 1 (PDPK1). PDPK1 protein stability was maintained by its binding to HSP90. Stomatin interacted with PDPK1 and interfered with the PDPK1–HSP90 complex formation, resulting in decreased PDPK1 expression. Knockdown of stomatin in cancer cells elevated Akt activation and promoted cell increase by promoting the interaction between PDPK1 and HSP90. Clinically, stomatin expression levels were significantly decreased in human prostate cancer samples with high Gleason scores, and lower expression of stomatin was associated with higher recurrence of prostate cancer after the operation. Collectively, these findings demonstrate the tumor-suppressive effect of stromal-induced stomatin on cancer cells.Significance:These findings reveal that interactions with stromal cells induce expression of stomatin in prostate cancer cells, which suppresses tumor growth via attenuation of the Akt signaling axis.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth
Supplementary Materials & Methods and Figures
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth
Supplementary Materials & Methods and Figures
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth
The growth and progression of cancers are crucially regulated by the tumor microenvironment where tumor cells and stromal cells are mutually associated. In this study, we found that stomatin expression was markedly upregulated by the interaction between prostate cancer cells and stromal cells. Stomatin suppressed cancer cell proliferation and enhanced apoptosis in vitro and inhibited xenograft tumor growth in vivo. Stomatin inhibited Akt activation, which is mediated by phosphoinositide-dependent protein kinase 1 (PDPK1). PDPK1 protein stability was maintained by its binding to HSP90. Stomatin interacted with PDPK1 and interfered with the PDPK1–HSP90 complex formation, resulting in decreased PDPK1 expression. Knockdown of stomatin in cancer cells elevated Akt activation and promoted cell increase by promoting the interaction between PDPK1 and HSP90. Clinically, stomatin expression levels were significantly decreased in human prostate cancer samples with high Gleason scores, and lower expression of stomatin was associated with higher recurrence of prostate cancer after the operation. Collectively, these findings demonstrate the tumor-suppressive effect of stromal-induced stomatin on cancer cells.Significance:These findings reveal that interactions with stromal cells induce expression of stomatin in prostate cancer cells, which suppresses tumor growth via attenuation of the Akt signaling axis.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth
The growth and progression of cancers are crucially regulated by the tumor microenvironment where tumor cells and stromal cells are mutually associated. In this study, we found that stomatin expression was markedly upregulated by the interaction between prostate cancer cells and stromal cells. Stomatin suppressed cancer cell proliferation and enhanced apoptosis in vitro and inhibited xenograft tumor growth in vivo. Stomatin inhibited Akt activation, which is mediated by phosphoinositide-dependent protein kinase 1 (PDPK1). PDPK1 protein stability was maintained by its binding to HSP90. Stomatin interacted with PDPK1 and interfered with the PDPK1–HSP90 complex formation, resulting in decreased PDPK1 expression. Knockdown of stomatin in cancer cells elevated Akt activation and promoted cell increase by promoting the interaction between PDPK1 and HSP90. Clinically, stomatin expression levels were significantly decreased in human prostate cancer samples with high Gleason scores, and lower expression of stomatin was associated with higher recurrence of prostate cancer after the operation. Collectively, these findings demonstrate the tumor-suppressive effect of stromal-induced stomatin on cancer cells.Significance:These findings reveal that interactions with stromal cells induce expression of stomatin in prostate cancer cells, which suppresses tumor growth via attenuation of the Akt signaling axis.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth